Additionally, in primary AML cells collected from human patients with different levels of SSTR2 expression, conjugate 10 showed 74 to 99% reduction of their clonogenic capacity in 5 of 6 patient samples (with a minor response of 45% reduction in the 6th sample), demonstrating its in vitro potential to eradicate leukemic stem cells, which are responsible for the appearance and propagation of AML disease [65]. This evidence concerns the gene SSTR2 and acute myeloid leukemia.